AIM ImmunoTech (STU:HXB2) Change In Payables And Accrued Expense : €5.87 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Change In Payables And Accrued Expense?

AIM ImmunoTech's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-0.38 Mil. It means AIM ImmunoTech's Accounts Payable & Accrued Expense declined by €0.38 Mil from Dec. 2023 to Mar. 2024 .

AIM ImmunoTech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €6.65 Mil. It means AIM ImmunoTech's Accounts Payable & Accrued Expense increased by €6.65 Mil from Dec. 2022 to Dec. 2023 .

AIM ImmunoTech Change In Payables And Accrued Expense Historical Data

The historical data trend for AIM ImmunoTech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Change In Payables And Accrued Expense Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.73

0.15

-0.17

0.52

6.65

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.45	0.94	1.72	3.60	-0.38

AIM ImmunoTech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.87 Mil.

AIM ImmunoTech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines